Hepatology

 
GLP-1RAs, SGLT-2 Inhibitors Tied to Lower Adverse Cardiovascular and Liver Events in Persons with T2D, MASLD
June 04, 2024

ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.

GLP-1RAs Linked to Lower Risk for Cirrhosis in Patients with MASLD, Type 2 Diabetes: Daily Dose
May 24, 2024

Your daily dose of the clinical news you may have missed.

Children of Parents with Obesity or Overweight Face Increased Risk of MASLD Later in Life
May 21, 2024

DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.

GLP-1 Agonists Reduce Risk of Cirrhosis, HCC in Adults with MASLD and T2D
May 20, 2024

DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.

The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
April 30, 2024

Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.

A MASLD Mantra to Practice By: Screen, Stage, Treat
April 29, 2024

Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.

The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
April 26, 2024

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
April 26, 2024

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

American Liver Foundation Announces First Federally-Funded Research on MASLD
April 26, 2024

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
April 24, 2024

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.